Capsaicin ( DrugBank: Capsaicin )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3
86	肺動脈性肺高血圧症	2
226	間質性膀胱炎（ハンナ型）	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03321019 (ClinicalTrials.gov)	December 12, 2017	20/10/2017	Airway Protective Mechanisms in PD (R01)	Mechanisms of Airway Protection Dysfunction in Parkinson's Disease	Parkinson Disease	Drug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluation	University of Florida	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	45 Years	85 Years	All	260		United States
2	NCT02390089 (ClinicalTrials.gov)	April 2015	19/2/2015	Cough According to Stimulus Type in PD	Airway Protection Deficits According to Stimulus Type in Parkinson's Disease	Parkinson's Disease	Drug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: Nebulizer	University of Florida	National Institute on Deafness and Other Communication Disorders (NIDCD)	Completed	50 Years	80 Years	All	158	Phase 1	United States
3	NCT02183519 (ClinicalTrials.gov)	October 2014	2/7/2014	Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease	Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease	Cough;Parkinson's Disease	Drug: Capsaicin;Other: Voluntary cough test	University of Florida	NULL	Completed	55 Years	85 Years	All	44	Phase 1/Phase 2	United States

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-001312-59-GB (EUCTR)	24/06/2011	15/04/2011	A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (treprostinil sodium), in Pulmonary Arterial Hypertension Patients - Efficacy of capsaicin 8% patches in Pulmonary Arterial Hypertension	A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (treprostinil sodium), in Pulmonary Arterial Hypertension Patients - Efficacy of capsaicin 8% patches in Pulmonary Arterial Hypertension	Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood pressure in the arteries to the lungs, rapidly evolving in a clinical syndrome of dyspnoea and fatigue and eventually leading to right ventricular failure and death. MedDRA version: 13.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders	Trade Name: Qutenza Product Name: Qutenza INN or Proposed INN: Capsaicin	Imperial College London	NULL	Not Recruiting			Female: yes Male: yes	0		United Kingdom
2	NCT01260454 (ClinicalTrials.gov)	November 2010	9/12/2010	The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain	The Qutenza® Patch for Disabling Treprostinil Infusion Site Pain	Pulmonary Hypertension;Pulmonary Arterial Hypertension	Drug: Qutenza (8% capsaicin)	University of Rochester	United Therapeutics	Completed	15 Years	80 Years	All	6	Phase 2	United States

226. 間質性膀胱炎（ハンナ型）

臨床試験数 : 145 / 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004316 (ClinicalTrials.gov)	June 1995	18/10/1999	Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis		Interstitial Cystitis;Vulvar Diseases	Drug: capsaicin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	University of Pittsburgh	Completed	18 Years	N/A	Female	139	Phase 1/Phase 2	NULL

先頭へ